Revvity Partners with Element Biosciences to Advance Neonatal Sequencing Solutions
- Revvity partners with Element Biosciences to enhance neonatal sequencing through an innovative IVD workflow solution.
- The collaboration aims to provide efficient and accessible diagnostic capabilities for newborn health in clinical settings.
- Revvity focuses on expanding genomic technologies, strengthening its market position in newborn health management.
Revvity Partners with Element Biosciences to Enhance Neonatal Sequencing Solutions
Revvity, Inc. has entered into a significant strategic agreement with Element Biosciences, Inc., marking a pivotal development in the field of neonatal health. This partnership focuses on the commercialization of an in vitro diagnostic (IVD) workflow solution specifically designed for neonatal sequencing. With Revvity's recent launch of an automated next-generation sequencing (NGS) workflow, this collaboration aims to advance the health of newborns through innovative genomic technologies and to provide enhanced diagnostic capabilities in clinical settings.
The partnership seeks to create a comprehensive IVD solution that is tailored to the unique needs of newborn sequencing. This includes immediate access to a research-use-only (RUO) version of the newborn sequencing workflow, which will incorporate various sample collection devices, automated nucleic acid extractors, and NGS library preparation kits. Yves Dubaquie, Revvity's senior vice president of diagnostics, emphasizes the importance of leveraging Revvity's expertise in newborn screening alongside Element's technological advancements. Together, they aim to develop efficient and accessible solutions that can be utilized in both research and clinical environments, thereby streamlining the process for healthcare professionals.
Element’s AVITI™ sequencing system will be integral to this IVD solution, facilitating a complete end-to-end workflow that supports groundbreaking neonatal research and meets the necessary regulatory approvals for advanced IVD applications. Yaron Hakak, Element's senior vice president of corporate and business development, underscores the significance of this collaboration in providing high-quality, tailored offerings for newborn screening programs worldwide. As both companies work together, they are set to enhance healthcare outcomes and foster the development of new diagnostic solutions within the neonatal sequencing landscape.
In addition to this strategic agreement, Revvity continues to focus on expanding its portfolio of genomic technologies aimed at improving healthcare outcomes. The collaboration with Element Biosciences not only strengthens Revvity's position in the market but also underscores the growing importance of genomic diagnostics in newborn health management.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…

